<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717728</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00021561</org_study_id>
    <nct_id>NCT02717728</nct_id>
  </id_info>
  <brief_title>Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy</brief_title>
  <official_title>Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy Pain Management: A Randomized Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently no standard of care or best practice for managing post-operative pain for&#xD;
      patients undergoing hip arthroscopy. Perioperative pain with these procedures can be&#xD;
      substantial. It has been shown that up to 90% of patients in the Post-anesthesia care unit&#xD;
      (PACU) following hip arthroscopy report pain scores of 7/10. Poor pain management following&#xD;
      hip fracture surgery directly results in increased time spent in high cost health care areas&#xD;
      and delayed time to ambulation. Continuous regional anesthesia following hip arthroplasty has&#xD;
      been shown to reduce narcotic consumption and related side-effects (reduction of&#xD;
      post-operative pain, delirium, and length of stay).&#xD;
&#xD;
      The purpose of this research is to evaluate the effectiveness of a fascia iliaca nerve block&#xD;
      in reducing post-operative pain within the first 24 hours following hip arthroscopy.&#xD;
      Additionally, the pharmacokinetics of the drug ropivacaine will be studied via laboratory&#xD;
      analysis of blood samples. Ultimately, the objective of this research is to develop a&#xD;
      standard of care or best practice for the management of post-operative pain following hip&#xD;
      arthroscopy. This study will include the entire age range of patients who are seen for hip&#xD;
      arthroscopy at Boston Children's Hospital, for which there is a 35 year age limit. Both sexes&#xD;
      will be included in the study.&#xD;
&#xD;
      The study design will be real catheter versus a sham catheter(control). All subjects will&#xD;
      receive general anesthesia. The catheters (real or sham) will be administered after the&#xD;
      induction of general anesthesia and before the beginning of the surgery until 24 hours after&#xD;
      recorded PACU admittance time. The anesthesia team placing the block will not be blinded. The&#xD;
      orthopaedic surgeon (Dr. Yen) and all evaluators will be blinded to the absence or presence&#xD;
      of a real catheter. In the case of a sham catheter, the anesthesia team will rig a pump to&#xD;
      look like it is dispensing local anesthesia.&#xD;
&#xD;
      To determine the pharmacokinetics of ropivicaine during standard fascia iliaca block,&#xD;
      following induction of general anesthesia, a large bore IV catheter will be inserted for the&#xD;
      purpose of blood draws (all patients).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, double-blinded, placebo controlled study. All patients who&#xD;
      are scheduled to undergo a hip arthroscopy with Dr. Yen who meet the inclusion/exclusion&#xD;
      criteria will be approached and informed consent and assent when indicated would be&#xD;
      obtained.Attending surgeon, anesthesia care team, PACU nursing staff, inpatient ward nursing&#xD;
      staff and evaluators will be blinded to study group. Regional Anesthesia team and pharmacy&#xD;
      staff will be not blinded to assignment of patient group but will have no additional contact&#xD;
      with patient after provision of sham or actual perineural catheter. the study design will be&#xD;
      real catheter versus a sham catheter, or control. All subjects will receive general&#xD;
      anesthesia. The catheters (real or sham) will be administered after the induction of general&#xD;
      anesthesia and before the beginning of the surgery until 24 hours after recorded PACU&#xD;
      admittance time. The anesthesia team placing the block will not be blinded. The orthopaedic&#xD;
      surgeon (Dr. Yen) and all evaluators will be blinded to the absence or presence of a real&#xD;
      catheter. In the case of a sham catheter, the anesthesia team will rig a pump to look like it&#xD;
      is dispensing local anesthesia.&#xD;
&#xD;
        1. General Anesthesia a) Induction (IV): i. propofol: 2-4 mg/kg [9] ii. fentanyl: 2 mcg/kg&#xD;
           administered iii. decadron: 4 mg as an antiemetic b) Airway: i. Airway management will&#xD;
           be chosen by the anesthesiologist in charge of the case.&#xD;
&#xD;
           c) Maintenance of anesthesia i. Sevoflurane 1.1 minimum alveolar concentration (MAC) ii.&#xD;
           If heart rate or blood pressure increase &gt; 20% above baseline (tachycardia as determined&#xD;
           the morning of surgery in the holding area), anesthesiologist will administer1&#xD;
           microgram/kg fentanyl as bolus. May repeat as often as every 10 minutes. Maximum 8&#xD;
           doses.&#xD;
&#xD;
           iii. With patient movement, anesthesiologist will administer propofol 1 mg/kg&#xD;
           intravenous push. May repeat every 5 minutes as necessary.&#xD;
&#xD;
           d) Emergence i. Discontinue isoflurane ii. Zofran 4 mg IV iii. Ketorolac 0.5 mg/kg IV;&#xD;
           max dose 30 mg.&#xD;
&#xD;
        2. Perineural Catheter:&#xD;
&#xD;
             -  Actual and sham will be hooked to infusion pump and receptacle&#xD;
&#xD;
             -  Pharmacy will label the infusion pumps, and will cover these labels in such a way&#xD;
                that the cover can be immediately at any point if needed.&#xD;
&#xD;
             -  Regional anesthesia team will double check the correct direction of the stopcock of&#xD;
                the tubing set.&#xD;
&#xD;
                a) Drug Group: i. Fascia Iliaca Catheter placement&#xD;
&#xD;
                  1. Administrator: Regional Anesthesiologist&#xD;
&#xD;
                       1. Minimum of three years anesthesia training&#xD;
&#xD;
                       2. Cannot be blinded, but will not contact/communicate with patient after&#xD;
                          surgery&#xD;
&#xD;
                  2. Appropriate laterality identified&#xD;
&#xD;
                  3. Site prepared using aseptic technique&#xD;
&#xD;
                  4. Localization of target site beneath fascia iliaca plane using portable&#xD;
                     ultrasound&#xD;
&#xD;
                       1. Aseptic preparation of probe with sterile sheath&#xD;
&#xD;
                       2. 38mm linear probe (BK Medical, USA)&#xD;
&#xD;
                       3. 15 MHz frequency&#xD;
&#xD;
                  5. Needle: 18g x 10mm echogenic enhanced needle&#xD;
&#xD;
                  6. 20G catheter inserted 3 cm beyond needle tip ii. Local anesthetic bolus&#xD;
&#xD;
                  1. Ropivacaine 0.5 ml/kg total in divided doses&#xD;
&#xD;
                     a. Aspirate every 5 ml&#xD;
&#xD;
                  2. Administered via needle iii. Dressing:&#xD;
&#xD;
                1. Liquid adhesive to skin 2. Sorbaview dressing (2x2) applied directly over&#xD;
                catheter on skin 3. Catheter coiled once on top sorbaview and clear plastic&#xD;
                dressing applied over sorbaview 4. 3x3 gauze taped over dressing to cover insertion&#xD;
                site 5. Catheter labeled: &quot;Fascia Iliaca Catheter&quot; b) Control Group i. Fascia&#xD;
                Iliaca Catheter placement&#xD;
&#xD;
                1. Administrator: Regional Anesthesiologist&#xD;
&#xD;
                  1. Minimum of three years anesthesia training&#xD;
&#xD;
                  2. Cannot be blinded, but will not contact/communicate with patient after surgery&#xD;
                     2. Appropriate laterality of surgery identified 3. Site prepared using aseptic&#xD;
                     technique 4. Localization of target site beneath fascia iliaca plane using&#xD;
                     portable ultrasound&#xD;
&#xD;
                a. Aseptic preparation of probe with sterile sheath b. 38mm linear probe (BK&#xD;
                Medical, USA) c. 15 MHz frequency 5. 20 g catheter tip laid at appropriate&#xD;
                insertion site ii. Dressing:&#xD;
&#xD;
                1. Liquid adhesive to skin 2. Sorbaview dressing (2x2) applied directly over&#xD;
                catheter on skin 3. Catheter coiled once on top sorbaview and clear plastic&#xD;
                dressing applied over sorbaview 4. 3x3 gauze taped over dressing to hide insertion&#xD;
                site 5. Catheter labeled: &quot;Fascia Iliaca Catheter&quot;&#xD;
&#xD;
        3. Infusion&#xD;
&#xD;
           a) Pharmacy to prepare and label all infusion syringes b) Actual content (ropivacaine&#xD;
           0.1%) to be covered but immediately available in case of need to know. Violation of&#xD;
           blinding to be obvious when tubing set removed. A non-blinded member of the study team&#xD;
           will remove the set.&#xD;
&#xD;
           i. Drug Group: Ropivacaine 0.1% ii. Control: Ropivacaine 0.1% to plastic bag c) Device:&#xD;
           bodyguard infusion pump d) Rate: 0.3 ml/kg/hr; max 15 to start within the first hour&#xD;
           after the block is placed.&#xD;
&#xD;
           e) Infusion bag to be changed out as needed by nursing staff per usual routine (depends&#xD;
           on volume of bag, weight of patient)&#xD;
&#xD;
        4. Surgical Procedure&#xD;
&#xD;
             1. Hip arthroscopy performed i. Pre-operative:&#xD;
&#xD;
                  1. Patient padded, per usual method&#xD;
&#xD;
                  2. Range Of Motion check by Yen and/or surgical staff&#xD;
&#xD;
                  3. Patient placed in traction device&#xD;
&#xD;
                  4. Xrays taken (AP pelvis, Dunn, frog leg, false profile). Must get view of&#xD;
                     lesion.&#xD;
&#xD;
                  5. Leg prepped/draped in normal fashion&#xD;
&#xD;
             2. At conclusion of surgical procedure, patients in both groups to receive standard&#xD;
                local anesthetic infiltration i. 20 cc total&#xD;
&#xD;
                  1. 10 ml 0.2% ropivacaine intra-articular into hip joint&#xD;
&#xD;
                  2. 5 ml 0.2% ropivacaine to each trochlear site (x2) Post-operative Methods&#xD;
&#xD;
           All patients will remain in the hospital for a minimum of 24 hours following surgery per&#xD;
           Dr. Yen's normal hip arthroscopy standard of care. A blinded observer will record pain&#xD;
           scores at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours postoperatively.&#xD;
           Pain scores will be measures at rest by an 11-point numeric rating scale (NRS) ranging&#xD;
           from 0-10, where 0 is no pain and 10 is worst pain imaginable. All patients should&#xD;
           complete the study and have measurements at each time point. Patient demographics&#xD;
           including age and gender as well as surgical characteristics including length of&#xD;
           surgery, estimated blood loss, and surgery type will be recorded.&#xD;
&#xD;
           Blinded observers will also record the time until patients require additional morphine,&#xD;
           the amount of morphine consumed at each time it was requested, and whether the patient&#xD;
           reported nausea or experienced vomiting within the first 24 hours post-operatively.&#xD;
&#xD;
        5. PACU a) Time 0 = PACU arrival time b) Pain scores: i. Obtained by trained, blinded nurse&#xD;
           observers ii. Recorded per policy with minimum evaluation every 15 minutes iii. Recorded&#xD;
           using 11 point numeric rating scale (NRS) 1. 0 = no pain; 10 = severe pain c) PCA&#xD;
           (patient controlled analgesia) available and initiated upon arrival to PACU i. Opioid:&#xD;
           morphine ii. Bolus dose: 0.025 mg/kg; lockout 10 minutes iii. Hourly limit: 0.15&#xD;
           mg/kg/hr iv. Nurse rescue bolus: 0.05 mg/kg; lockout 60 minutes 1. To be administered&#xD;
           for NRS &gt; 7 v. continuous hourly infusion = 0&#xD;
&#xD;
        6. Inpatient Wards&#xD;
&#xD;
             1. Nurses will evaluate pain per usual practice. Documented minimum every 4 hours. i.&#xD;
                pain scores &gt;7, nurse will administer: nurse rescue bolus via PCA ii. No dermatome&#xD;
                test to prevent the introduction of bias by inadvertently un-blinding subjects.&#xD;
&#xD;
      Pharmacokinetic Methods To determine the pharmacokinetics of ropivicaine during standard&#xD;
      fascia iliaca block [10-13].&#xD;
&#xD;
        1. Following induction of general anesthesia, a large bore IV catheter will be inserted for&#xD;
           the purpose of blood draws (all patients)&#xD;
&#xD;
        2. Blood Sampling (all patients)&#xD;
&#xD;
             1. Volume 2ml&#xD;
&#xD;
             2. Time = zero defined as immediately following bolus of ropivicaine or sham&#xD;
                equivalent&#xD;
&#xD;
             3. First hour: collected at 5, 10, 15, 30, 35, and 60 minutes.&#xD;
&#xD;
        3. Analysis:&#xD;
&#xD;
             1. Internal lab&#xD;
&#xD;
             2. Blood samples will be centrifuged to separate the plasma and stored at -20 degrees&#xD;
                C until assay. Plasma ropivacaine levels analyzed by gas chromatography&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The investigators will measure morphine consumption as the endpoint, to compare the efficacy of each group</measure>
    <time_frame>Within the first 24hs after the fascia iliaca block is placed.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The investigators will collect postoperative pain scores using the 11 point numeric rating scale in each group, to compare the efficacy of each group</measure>
    <time_frame>Within the first 24hs after the fascia iliaca block is placed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will collect time to first opioid consumption in each group, To compare the efficacy of each group.</measure>
    <time_frame>Within the first 24hs after the fascia iliaca block is placed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will document incidence of postoperative nausea and vomiting in each group.</measure>
    <time_frame>Within the first 24hs after the fascia iliaca block is placed.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will measure maximum plasma concentrations at specific time intervals of 0.2% ropivacaine administered via a fascia iliaca block.</measure>
    <time_frame>Within the first hour after the fascia iliaca block is placed.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Hip Surgery Corrective</condition>
  <condition>Anesthesia; Functional</condition>
  <arm_group>
    <arm_group_label>Drug group Fascia iliaca nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses&#xD;
Device: Dressing: Catheter labeled: &quot;Fascia Iliaca Catheter&quot;&#xD;
Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group sham nerve block</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)&#xD;
Device: Dressing: Catheter labeled: &quot;Fascia Iliaca Catheter&quot;&#xD;
Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Drug group Fascia iliaca nerve block</intervention_name>
    <description>Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.&#xD;
Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.&#xD;
Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.</description>
    <arm_group_label>Drug group Fascia iliaca nerve block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control group sham nerve block</intervention_name>
    <description>Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.&#xD;
Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.&#xD;
Device: Dressing&#xD;
Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs.</description>
    <arm_group_label>Control group sham nerve block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age at surgery is 12-35.&#xD;
&#xD;
          2. Able to provide informed consent and/or assent.&#xD;
&#xD;
          3. Diagnosis is Femoro-acetabular impingement (FAI) and/or labral tear.&#xD;
&#xD;
          4. Surgery will involve and be limited to hip arthroscopy and osteoplasty of the&#xD;
             acetabular rim or femoral head/neck junction.&#xD;
&#xD;
          5. Surgery will be performed by Dr. Yi-Meng Yen.&#xD;
&#xD;
          6. Admission status: 24 hour admission to hospital.&#xD;
&#xD;
          7. No contraindication to study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hip revision surgery&#xD;
&#xD;
          2. Underlying neurologic disorder affecting pain perception.&#xD;
&#xD;
          3. Underlying neurocognitive disorder or developmental delay affecting ability to convey&#xD;
             feelings of pain to medical staff.&#xD;
&#xD;
          4. Underlying opioid use or addiction.&#xD;
&#xD;
          5. Significant concomitant hip pathology.&#xD;
&#xD;
          6. Active infection over catheter site.&#xD;
&#xD;
          7. History of chronic pain (not localized to the hip) requiring consistent opioid&#xD;
             consumption for greater than or equal to 6 months within year prior to surgery.&#xD;
&#xD;
          8. Allergy to local anesthetics&#xD;
&#xD;
          9. Allergy to fentanyl&#xD;
&#xD;
         10. Allergy to midazolam&#xD;
&#xD;
         11. Allergy to morphine&#xD;
&#xD;
         12. American Society of Anesthesia class 3 or higher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Meng Yen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wasin Luckanavanich, Coordinator</last_name>
    <phone>857-218-3272</phone>
    <email>wasin.luckanavanich@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>karen r boretsky, md</last_name>
    <phone>4128187798</phone>
    <email>karen.boretsky@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Wasin Luckanavanich, Coordinator</last_name>
      <phone>857-218-3272</phone>
      <email>wasin.Luckanavanich@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Karen R Boretsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Meng Yen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Paut O, Schreiber E, Lacroix F, Meyrieux V, Simon N, Lavrut T, Camboulives J, Bruguerolle B. High plasma ropivacaine concentrations after fascia iliaca compartment block in children. Br J Anaesth. 2004 Mar;92(3):416-8. Epub 2004 Jan 22.</citation>
    <PMID>14742340</PMID>
  </reference>
  <results_reference>
    <citation>Ward JP, Albert DB, Altman R, Goldstein RY, Cuff G, Youm T. Are femoral nerve blocks effective for early postoperative pain management after hip arthroscopy? Arthroscopy. 2012 Aug;28(8):1064-9. doi: 10.1016/j.arthro.2012.01.003. Epub 2012 Apr 11.</citation>
    <PMID>22498045</PMID>
  </results_reference>
  <results_reference>
    <citation>Morrison SR, Magaziner J, McLaughlin MA, Orosz G, Silberzweig SB, Koval KJ, Siu AL. The impact of post-operative pain on outcomes following hip fracture. Pain. 2003 Jun;103(3):303-311. doi: 10.1016/S0304-3959(02)00458-X.</citation>
    <PMID>12791436</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith HS, Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacol. 2014 Jan 5;722:67-78. doi: 10.1016/j.ejphar.2013.09.074. Epub 2013 Oct 21. Review.</citation>
    <PMID>24157979</PMID>
  </results_reference>
  <results_reference>
    <citation>Marino J, Russo J, Kenny M, Herenstein R, Livote E, Chelly JE. Continuous lumbar plexus block for postoperative pain control after total hip arthroplasty. A randomized controlled trial. J Bone Joint Surg Am. 2009 Jan;91(1):29-37. doi: 10.2106/JBJS.H.00079.</citation>
    <PMID>19122076</PMID>
  </results_reference>
  <results_reference>
    <citation>Rashiq S, Vandermeer B, Abou-Setta AM, Beaupre LA, Jones CA, Dryden DM. Efficacy of supplemental peripheral nerve blockade for hip fracture surgery: multiple treatment comparison. Can J Anaesth. 2013 Mar;60(3):230-43. doi: 10.1007/s12630-012-9880-8. Epub 2013 Jan 19. Review.</citation>
    <PMID>23334780</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>August 29, 2020</last_update_submitted>
  <last_update_submitted_qc>August 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Karen Boretsky</investigator_full_name>
    <investigator_title>Dr. Karen Boretsky</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

